Albano, F., Browning, S., Li, F., Bar, N., Parker, T., Anderson, T., Stevens, E., VanOudenhove, J., Matthews, M., Gorshein, E., Haldas, J., Talsania, A., Sabbath, K., Seropian, S., Halene, S., Perna, F., Neparidze, N. (2025). Target antigen density may impact clinical response in patients with relapsed/refractory multiple myeloma undergoing treatment with elotuzumab and belantamab mafodotin. Blood. https://doi.org/10.1182/blood-2025-7578